• 医学文献
  • 知识库
  • 评价分析
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
  • 临床诊疗知识库
  • 中医药知识库
  • 机构
  • 作者
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

医学文献>>
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
热搜词:
换一批

氧化型低密度脂蛋白在早期预测川崎病冠状动脉损害中的价值

Early prediction of the risk of coronary artery lesions in K awasaki disease by oxidized low-density lipoproteins

摘要目的 观察川崎病急性期血浆氧化型低密度脂蛋白(oxLDL)的表达,探讨oxLDL在早期预测川崎病冠状动脉损害中的价值.方法 确诊为川崎病的患儿80例,根据不同时期超声结果分为4组:急性期、亚急性期均有冠状动脉损害组(CAL1组)8例、急性期有冠状动脉损害,亚急性期恢复正常组(CAL2组)10例;急性期冠状动脉正常,亚急性期出现冠状动脉损害组(NCAL1组)10例和急性期和亚急性期均无冠状动脉损害组(NCAL2组)52例.于急性期(静脉丙种球蛋白使用前)采集静脉血.同时收集本院住院的发热患儿及门诊体检的健康儿童各20名为发热对照组和健康对照组,采集静脉血.血浆oxLDL浓度检测采用双抗体夹心固相ELISA,均数比较采用单因素方差分析,两两比较用LSD-t检验.并行受试者工作特征曲线(ROC曲线)分析确定界限值.结果 川崎病患儿急性期无论有无冠状动脉损害血浆oxLDL含量均高于对照组,差异有统计学意义[CAL组(15.0±3.3)mU/L,NCAL组(12.3±3.5)mU/L与发热对照组(9.2±2.2)mU/L,健康对照组(8.0±2.3)mU/L;F=20.435,P<0.05].与冠状动脉无损害的川崎病患儿相比,有冠状动脉损害患儿血浆oxLDL升高更为明显[(15.0±3.3)mU/L与(12.3±3.5)mU/L,t=2.89,P=0.002].川崎病各组间比较差异有统计学意义(F=5.068,P=0.003),NCAL1组与NCAL2组相比血浆oxLDL含量升高,差异有统计学意义[(14.5±3.8)mU/L与(11.9±3.3)mU/L,t=2.29,P=0.02],而与急性期即有冠状动脉损害的CAL1组[(15.9±3.9)mU/L]、CAL2组[(14.2±2.7)mU/L]比较差异无统计学意义(t值分别为0.73和0.20,P分别为0.41,0.84)].ROC曲线分析oxLDL≥13.83 mU/L时,预测冠状动脉损害的灵敏度为0.607,特异度为0.75.结论 oxLDL在川崎病冠状动脉损害中具有一定作用;川崎病冠状动脉内皮功能障碍早于冠状动脉扩张,oxLDL有望成为早期预测川崎病冠状动脉损害的一个可靠指标.

更多

abstractsObjective To study the expression of plasma oxidized low-density lipoprotein (oxLDL) in children with acute phase Kawasaki disease (KD), and investigate its value for early prediction of coronary artery lesions in KD. Methods Totally 80 children with KD were collected. Children were divided into four groups by the results of echocardiogram of coronary artery in different periods: CAL1 group (children with coronary artery lesions (CAL+) both in acute and sub-acute phase, 8 cases), CAL2 group (children with CAL+in acute phase but recovery normal (CAL-) in sub-acute phase, 10 cases), NCAL1 group (children with CAL-in acute phase but occur CAL+ in sub-acute phase, 10 cases) and NCAL2 group (children with CAL- both in acute and sub-acute phase, 52 cases). The serum samples (before the use of intravenous immunoglobulin) were collected in acute phase. Twenty healthy controls and twenty fever controls were enrolled into the study, and their serum samples were collected. OxLDL was measured by enzyme linked immunosorbent assay (ELISA). They were compared using ANOVA, pairwise comparison LSD-t test. And ROC curve analysis was used to determine the threshold. Results Compared with the control groups,plasma oxLDL levels were higher in children with KD, both CA+and CAL-[(15.0±3.3) mU/L, (12.3±3.5) mU/L vs (9.2±2.2) mU/L, (8.0±2.3) mU/L, F=20.435, P<0.05]. Plasma oxLDL levels were increased more significantly in children with CAL+ than children with CAL- in KD [(15.0 ±3.3) mU/L vs (12.3 ±3.5) mU/L, t=2.28, P=0.002]. There was significant difference in the concentration of oxLDL between the groups of Kawasaki disease (F=5.068, P=0.003). Plasma oxLDL levels were significantly higher in the NCAL1 group than those in the NCAL2 group [(14.5 ±3.8) mU/L vs (11.9±3.3) mU/L, t=2.29, P=0.02], but there were no statistically significant difference between the NCAL1 group and CAL1 or CAL2 group [(14.5±3.8) mU/L vs (15.9±3.9) mU/L, (14.5±3.8) mU/L vs (14.2±2.7) mU/L, t=0.73, 0.20;P=0.41, 0.84]. ROCs analysis indicated that oxLDL≥13.83 mU/L, could be the threshold for the prediction of coronary artery lesions with the sensitivity of 0.607 and a specificity of 0.75. Conclusion OxLDL plays an important role in coronary artery lesions in KD. The coronary endothelial dysfunction is earlier than coronary dilatation, and oxLDL is expected to become a reliable early predictor of coronary artery lesions in KD.

More
广告
栏目名称 论著
DOI 10.3760/cma.j.issn.1007-7480.2017.07.003
发布时间 2017-08-24
基金项目
浙江省自然科学基金 浙江省医药卫生科技项目(2017KY465)Natural Science Foundation of Zhejiang Province of China Medical Technology Science of Zhejiang Province
  • 浏览318
  • 下载133
中华风湿病学杂志

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

扩展文献

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷